Literature DB >> 28332708

Dual-specificity tyrosine phosphorylation-regulated kinase 2 regulates osteoclast fusion in a cell heterotypic manner.

Gali Guterman-Ram1, Milena Pesic1, Ayelet Orenbuch1, Tal Czeiger1, Anastasia Aflalo1, Noam Levaot1,2.   

Abstract

Monocyte fusion into osteoclasts, bone resorbing cells, plays a key role in bone remodeling and homeostasis; therefore, aberrant cell fusion may be involved in a variety of debilitating bone diseases. Research in the last decade has led to the discovery of genes that regulate osteoclast fusion, but the basic molecular and cellular regulatory mechanisms underlying the fusion process are not completely understood. Here, we reveal a role for Dyrk2 in osteoclast fusion. We demonstrate that Dyrk2 down regulation promotes osteoclast fusion, whereas its overexpression inhibits fusion. Moreover, Dyrk2 also promotes the fusion of foreign-body giant cells, indicating that Dyrk2 plays a more general role in cell fusion. In an earlier study, we showed that fusion is a cell heterotypic process initiated by fusion-founder cells that fuse to fusion-follower cells, the latter of which are unable to initiate fusion. Here, we show that Dyrk2 limits the expansion of multinucleated founder cells through the suppression of the fusion competency of follower cells.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Dyrk2; cell fusion; heterotypic fusion; osteoclast; osteoclast fusion

Mesh:

Substances:

Year:  2017        PMID: 28332708     DOI: 10.1002/jcp.25922

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  2 in total

1.  Schlafen2 mutation in mice causes an osteopetrotic phenotype due to a decrease in the number of osteoclast progenitors.

Authors:  Ibrahim Omar; Gali Guterman-Ram; Dolev Rahat; Yuval Tabach; Michael Berger; Noam Levaot
Journal:  Sci Rep       Date:  2018-08-29       Impact factor: 4.379

Review 2.  DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells.

Authors:  Chun Shik Park; H Daniel Lacorazza
Journal:  Exp Mol Med       Date:  2020-10-16       Impact factor: 8.718

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.